Five-day aprepitant versus fosaprepitant in patients receiving cisplatin

the ONA take:

Single administration of fosaprepitant meglumine was no less effective than 5-day administration of aprepitant for preventing acute and delayed nausea and vomiting symptoms occurring after administration of cisplatin-based chemotherapy regimens, a new study published online in the journal Supportive Care in Cancer has shown.

For the study, researchers sought to compare the impact of 5-day aprepitant with single administration of fosaprepitant meglumine, the intravenous formulation of aprepitant, on the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic cisplatin-based chemotherapy.

Researchers enrolled 101 patients who received chemotherapy for esophageal, gastric, head and neck, or lung cancer with a regimen containing cisplatin 60 mg/m2 or higher. Participants were randomly assigned to receive either aprepitant for 5 days or one dose of fosaprepitant meglumine.

Results showed no significant differences in the complete response rate or the complete control rate over the 7-day period following the first cisplatin administration.

Five-day aprepitant versus fosaprepitant in patients receiving cisplatin
Single administration of fosaprepitant meglumine no less effective for preventing acute and delayed nausea and vomiting symptoms.
We aimed to compare the preventive effect of 5-day administration of aprepitant with single administration of fosaprepitant meglumine against nausea and vomiting symptoms due to highly emetogenic chemotherapy regimens comprising cisplatin (CDDP).
READ FULL ARTICLE From Springer
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs